Thrombosis News and Research

Latest Thrombosis News and Research

In pregnant women, DVT more likely to occur on left side

Deep vein thrombosis (DVT) in pregnant patients is more likely to occur on the left side, and in particular in the left leg, write the authors of a Review article in CMAJ (Canadian Medical Association Journal) http://www.cmaj.ca/embargo/cmaj091692.pdf.

30 Mar 2010

NIH grants $1.4 Million to WPI to continue study of arterial plaque

A Worcester Polytechnic Institute research team has received a four-year, $1.4 million award from the National Institutes of Health to continue a groundbreaking study of arterial plaque. This research could lead to tools that will enable physicians to predict the likelihood of plaque rupture, which is responsible for most heart attacks and strokes.

25 Mar 2010

Physician scientists present new findings on aspirin therapy, atrial fibrillation drug therapy and LVAD

Physician scientists from the Cedars-Sinai Heart Institute presented new findings on the effectiveness of routine aspirin therapy for preventing heart disease, a drug therapy for atrial fibrillation and the role left ventricular assist devices may play in weight reduction for obese patients with chronic end-stage heart failure who are considered for heart transplantation.

19 Mar 2010

Phase 1B clinical study initiated to evaluate safety and efficacy of PMX-60056

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has initiated a Phase 1B clinical study to evaluate the safety and efficacy of PMX-60056 in reversing the anticoagulant activity of low molecule weight heparin (LMWH).

19 Mar 2010

CYPHER Sirolimus-eluting Coronary Stent demonstrates efficacy advantages over Medtronic's Endeavor

Investigators reported the long-term follow-up of the largest randomized comparison between the CYPHER(R) Sirolimus-eluting Coronary Stent and Medtronic's Endeavor(R) Stent highlighting significant and sustained clinical differences. These important findings were presented at the American College of Cardiology annual meeting, (ACC 2010) in Atlanta and published on-line in the prestigious journal The Lancet.

18 Mar 2010

OrbusNeich's Genous Bio-engineered R stent demonstrates long term clinical efficacy

OrbusNeich today announced that 12 month follow up data from real world patients demonstrated long term clinical efficacy of the company's Genous Bio-engineered R stent.

18 Mar 2010

Abraxis BioScience's Phase 3 trial comparing ABRAXANE with Taxol injection meets primary endpoint

Abraxis BioScience, Inc. today announced that its randomized registrational Phase 3 clinical trial comparing ABRAXANE® (protein-bound paclitaxel) with Taxol® (paclitaxel) injection, both in combination with carboplatin, met the study’s primary endpoint by demonstrating that ABRAXANE showed a significant improvement in overall response rate as compared to Taxol, in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC), as assessed by independent radiologist review.

17 Mar 2010

Liver cancer: Treatment with intra-arterial yttrium-90 microspheres promising

An interventional radiology treatment-the use of intra-arterial yttrium-90 microspheres for liver cancer (also known as hepatocellular carcinoma)-shows promise in prolonging life for many patients with this devastating condition, according to researchers at the Society of Interventional Radiology's 35th Annual Scientific Meeting in Tampa, Fla.

17 Mar 2010

TRITON-TIMI 38 study evaluates response rates in patients with common genetic variant in ABCB1 gene

A new analysis of the TRITON-TIMI 38 study evaluated response rates in patients with a common genetic variant in the ABCB1 gene. Patients enrolled in the TRITON-TIMI 38 study were treated with dual antiplatelet therapy with either Plavix® (clopidogrel) plus aspirin or Effient® (prasugrel) plus aspirin and managed with percutaneous coronary intervention (PCI) following an acute coronary syndrome (ACS) event.

17 Mar 2010

Genetic test helps reduce hospitalization rates for heart patients on warfarin

Hospitalization rates for heart patients taking warfarin, the world's most-prescribed blood thinner, dropped by approximately 30 percent when genetic information was available to doctors prescribing the drug, researchers from Medco Health Solutions, Inc.-- in association with the Medco Research Institute™ -- and Mayo Clinic announced today.

17 Mar 2010

Patent applications continue to alter medical landscape to improve patient care

Over the past 40 years, more than 2,400 patents and patent applications-pioneering modern medicine with the devices and drugs that advance minimally invasive treatments-have been filed by members of the Society of Interventional Radiology.

17 Mar 2010

PERSEUS clinical program demonstrates positive results of TAXUS Element Paclitaxel-Eluting Stent System

Boston Scientific Corporation today announced 12-month results from its PERSEUS clinical program that demonstrated positive safety and efficacy outcomes in workhorse lesions for the platinum chromium TAXUS® Element™ Paclitaxel-Eluting Stent System compared to the TAXUS® Express2™ Paclitaxel-Eluting Stent System.

16 Mar 2010

Medtronic' Endeavor DES demonstrates safety and efficacy profile for coronary artery disease treatment

The consistency and quality of the long-term clinical results for the Endeavor® drug-eluting stent (DES) from Medtronic, Inc., continue to distinguish it as a treatment for coronary artery disease, according to newly released data.

16 Mar 2010

PERSEUS clinical program comparing TAXUS Element Stent to prior-generation stents: 12-month results

Angiotech Pharmaceuticals, Inc. today announced that its corporate partner, Boston Scientific Corporation, announced 12-month results from its PERSEUS clinical program that demonstrated positive safety and efficacy outcomes in workhorse lesions for the platinum chromium TAXUS(R) Element(TM) Paclitaxel-Eluting Stent System compared to the TAXUS(R) Express(TM) Paclitaxel-Eluting Stent System.

16 Mar 2010

Boston Scientific announces results from HORIZONS AMI trial assessing Express bare-metal stent

Boston Scientific Corporation today announced results from an analysis of one-year subset data from the HORIZONS AMI trial assessing the impact of diabetes on clinical and angiographic outcomes in heart attack patients treated with the TAXUS® Express2™ Paclitaxel-Eluting Stent System or the Express® bare-metal stent.

16 Mar 2010

CYPHER Sirolimus-eluting Coronary Stent provides better outcome compared to Medtronic’s Endeavor Stent

Investigators reported the long-term follow-up of the largest randomized comparison between the CYPHER® Sirolimus-eluting Coronary Stent and Medtronic’s Endeavor® Stent highlighting significant and sustained clinical differences. These important findings were presented at the American College of Cardiology annual meeting, (ACC 2010) in Atlanta and published on-line in the prestigious journal The Lancet.

16 Mar 2010

Cook Medical launches new NavAlign femoral delivery system at SIR Annual Scientific Meeting

Physicians placing inferior vena cava (IVC) filters to prevent life-threatening pulmonary emboli now have access to the latest iteration of Cook Medical’s advanced NavAlign™ delivery system, a deployment system designed to minimize the risk of vessel trauma and streamline filter placement.

15 Mar 2010

Regado Biosciences announces first successful subcutaneous application of an aptamer

Regado Biosciences, Inc., a privately held company leading the development of antithrombotic aptamers with active control agents, announced that Chris Rusconi, PhD, Senior Vice President, Chief Scientific Officer and Steven Zelenkofske, DO, FACC, Senior Vice President , Chief Medical Officer presented an abstract at the American College of Cardiology on Monday, March 15, 2010 in Atlanta, Georgia.

15 Mar 2010

Positive results from second phase of ABSORB clinical trial on BVS technology

Abbott today announced positive 30-day results from the first 101 patients enrolled in the second phase of the ABSORB trial. Patients treated with Abbott's bioresorbable vascular scaffold (BVS), under clinical investigation in Europe, demonstrated no cases of blood clots (thrombosis), no need for repeat procedures (ischemia-driven target lesion revascularization) and a very low rate of major adverse cardiac events (MACE(1) rate of 2.0 percent) at 30 days.

15 Mar 2010

ACCORD Lipid trial: New research into atherogenic dyslipidemia in type 2 diabetes

Cardiovascular risk can be reduced by an additional 31 percent in type 2 diabetes patients with atherogenic dyslipidemia, the common combination of elevated triglycerides (TG, 204 mg/dL or 2.3 mmol/L or higher) and low levels of high-density lipoprotein cholesterol (HDL-C, 34 mg/dL or 0.88 mmol/L or lower).

15 Mar 2010

Thrombosis News and Research

Latest Thrombosis News and Research

In pregnant women, DVT more likely to occur on left side

NIH grants $1.4 Million to WPI to continue study of arterial plaque

Physician scientists present new findings on aspirin therapy, atrial fibrillation drug therapy and LVAD

Phase 1B clinical study initiated to evaluate safety and efficacy of PMX-60056

CYPHER Sirolimus-eluting Coronary Stent demonstrates efficacy advantages over Medtronic's Endeavor

OrbusNeich's Genous Bio-engineered R stent demonstrates long term clinical efficacy

Abraxis BioScience's Phase 3 trial comparing ABRAXANE with Taxol injection meets primary endpoint

Liver cancer: Treatment with intra-arterial yttrium-90 microspheres promising

TRITON-TIMI 38 study evaluates response rates in patients with common genetic variant in ABCB1 gene

Genetic test helps reduce hospitalization rates for heart patients on warfarin

Patent applications continue to alter medical landscape to improve patient care

PERSEUS clinical program demonstrates positive results of TAXUS Element Paclitaxel-Eluting Stent System

Medtronic' Endeavor DES demonstrates safety and efficacy profile for coronary artery disease treatment

PERSEUS clinical program comparing TAXUS Element Stent to prior-generation stents: 12-month results

Boston Scientific announces results from HORIZONS AMI trial assessing Express bare-metal stent

CYPHER Sirolimus-eluting Coronary Stent provides better outcome compared to Medtronic’s Endeavor Stent

Cook Medical launches new NavAlign femoral delivery system at SIR Annual Scientific Meeting

Regado Biosciences announces first successful subcutaneous application of an aptamer

Positive results from second phase of ABSORB clinical trial on BVS technology

ACCORD Lipid trial: New research into atherogenic dyslipidemia in type 2 diabetes

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Thrombosis News and Research

Latest Thrombosis News and Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in